Lyrica, Pfizer’s blockbuster anticonvulsive treatment, is expected to come off-patent in December 2018,...
- Pfizer’s blockbuster drug Lyrica comes off-patent in 2018
- Unlocking cell-free protein synthesis: biotech’s next big ticket?
- FDA files legal complaint against BioDefense
- ASCO 2018: combinations vs single agent in melanoma immunotherapy
- ASCO 2018: after Revlimid results, is superior safety worth the cost?
Pfizer’s blockbuster drug Lyrica comes off-patent in 2018
Lyrica, Pfizer’s blockbuster anticonvulsive treatment, is expected to come off-patent in December 2018, leading to a dramatic reduction in sales due to generic erosion.
Unlocking cell-free protein synthesis: biotech’s next big ticket?
A Northwestern University-led research team has invented a new method of manufacturing proteins outside of a cell, an innovation with major implications for biotech. Abi Millar speaks to the team to find out more about the potential of this cell-free protein synthesis platform.
GE provides FlexFactory platform to Xiangxue Pharmaceutical
GE Healthcare has agreed to supply its FlexFactory manufacturing platform to China-based Xiangxue Pharmaceutical for high-affinity and high-specificity T cell receptor (TCR) cell immunotherapy drugs.
Nymi Enters Into Strategic Partnership With Konica Minolta
Nymi has announced that it has entered a strategic partnership with Konica Minolta that includes a financial investment by Konica Minolta in Nymi.
Can Cimzia approval secure UCB’s position in immuno-dermatology?
On 28 May, the FDA approved the extension of the label of UCB’s tumor necrosis factor (TNF) inhibitor Cimzia (certolizumab pegol) for use in adults with moderate-to-severe plaque psoriasis.
ASCO 2018: combinations vs single agent in melanoma immunotherapy
One of the very first sessions at this year’s ASCO meeting was an education session that neatly summarised the current status of immunotherapy combination research in melanoma. The indication in which the anti-PD-1 checkpoint inhibitor revolution began back in 2014, melanoma continues to serve as a testing ground for novel strategies.
ASCO 2018: after Revlimid results, is superior safety worth the cost?
Data from the Phase III RELEVANCE trial assessing Revlimid (lenalidomide) plus rituximab in first-line follicular lymphoma was presented by Nathan Fowler, MD, during the third day of the 2018 Annual American Society of Clinical Oncology (ASCO) conference in Chicago.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.